ClearOne experienced a dramatic pre-market move, with the stock jumping 90.2% after the company disclosed that holders representing approximately 61.3% of its voting stock delivered written consent approving the issuance of 12.5 million new common shares to Vivani Medical. That share issuance is a material condition for completing ClearOne's proposed merger with Cortigent, Inc., and the approval was revealed in an after-hours filing dated August 5.
The news materially altered the perceived timeline risk around the transaction and lifted the company's pre-market price to $7.00. Market participants reacted to the filing as a de-risking event because the shareholder consent addresses a key closing condition for the deal.
ClearOne's filing included two additional deal-related actions that investors interpreted as further progress toward the merger close. The company announced it canceled First Finance's warrants to buy 437,500 shares, a step the company described as simplifying its capital structure. At the same time, ClearOne disclosed an employment agreement for Chief Financial Officer Simon Brewer that becomes effective upon the deal's closing, signaling management continuity through the planned transition.
Those disclosures were significant because they accompany a strategic transformation. ClearOne is positioning to move away from its legacy audio-visual communications business toward a neurostimulation and brain-computer interface platform under the proposed Cortigent Holdings name. The company characterized the shift as high-risk and high-potential, and the recent approvals were presented by ClearOne as meaningful milestones in that pivot.
Broader market action offered little support for the surge. The S&P 500 and Dow Jones posted only modest gains while the Nasdaq ticked slightly lower, which indicates the sharp pre-market move in ClearOne shares was driven by company-specific developments rather than by a general rally in equities.
The Cortigent transaction itself was first announced on July 1-2, 2026, and has been a catalyst for extreme volatility in the stock since that announcement. With the newly disclosed shareholder consent and related steps, speculative interest has been reignited as the companies target a Q3 2026 closing window.
Context and implications
In sum, the written consent approving the Vivani Medical share issuance, the cancellation of First Finance's warrants, and the CFO employment agreement together reduce identifiable execution risks tied to the merger and mark substantive steps toward completing the transaction. However, the transaction has not closed, and the company remains in a transition toward a different end-market focus.